Skip to main content

ADARx Pharmaceuticals, Inc.

corporate_fare Company Profile

ADARx Pharmaceuticals, Inc.

ADRX·NASDAQ·Life Sciences·CIK 0001802369

ADARx Pharmaceuticals is a clinical-stage biotechnology company that develops siRNA therapeutics for various diseases. The company's portfolio includes hepatic-targeted programs and extrahepatic-targeted programs. Its hepatic-targeted programs feature Agazisiran, a complement factor B (CFB) program, which is a single therapeutic candidate with potential for multiple indications. Also in this category is Onvuzosiran, a clinical program aimed at preventing hereditary angioedema (HAE) attacks, and ADX-626, a Factor XI (FXI) program for secondary stroke prevention, with additional clinical potential for stroke prevention in atrial fibrillation. The extrahepatic-targeted programs include ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass. Another extrahepatic program is ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. ADARx Pharmaceuticals was incorporated in 2019 and is located in San Diego, California.

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for ADRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for ADRX spans 8-K, 4, 424B4.

Recent high-impact activity:

  • ADARx Posts Q3 Loss, $901M Cash Into 2030, New Onvuzosiran Phase 2a Data
  • ADARx Posts $901M Cash Pile, Says Funding Lasts Into 2030
  • ADARx Fully Exercises Underwriters' Option, IPO Proceeds Reach $513M
  • OrbiMed Buys $16.15M in ADARx IPO, Converts 23.3M Preferred Shares
  • Director George Simeon Buys $27.2M of ADARx Stock at IPO Price

Short Interest & Short Volume

5.02 days to cover

FINRA reported short interest of 1,801,373 shares in ADRX as of the October 30, 2026 settlement, a 5.4% decrease from the prior period — about 5.0 days to cover at its recent average daily volume. On November 20, 2026, 60.5% of ADRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,801,373 shares as of October 30, 2026
Change vs prior period▼ 5.4%
Days to cover5.02 at avg daily volume of 358,545
Daily short volume (FINRA facilities)60.5% of 281,788 shares on November 20, 2026
5-day average short volume68.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ADRX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-26.

1 recent capital raise

Upsized IPO Priced at $17.00/Share · AbbVie Concurrent Private Placement

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$12.79
52-week range · as of 2026-11-12 $12.5 – $23.21
Market cap
$1.42B
Volume
708.8K (1.6× avg)
3-mo avg 450.2K
Live data · 2026-11-21 19:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ADRX - Latest Insights

ADRX
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.91
Real-time Price: $12.79 info
Change: -$2.12 (-14%) info
Market Cap: $1.422B info
ADRX
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.91
Real-time Price: $12.79 info
Change: -$2.12 (-14%) info
Market Cap: $1.422B info
ADRX
Oct 01, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.57
Real-time Price: $12.79 info
Change: -$6.78 (-35%) info
Market Cap: $1.422B info
ADRX
Sep 30, 2026, 5:23 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $20.30
Real-time Price: $12.79 info
Change: -$7.51 (-37%) info
Market Cap: $1.422B info
ADRX
Sep 29, 2026, 9:43 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $20.63
Real-time Price: $12.79 info
Change: -$7.84 (-38%) info
Market Cap: $1.422B info
ADRX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.09
Real-time Price: $12.79 info
Change: -$7.30 (-36%) info
Market Cap: $1.422B info
ADRX
Sep 25, 2026, 8:11 PM EDT
Filing Type: 424B4
Importance Score:
8
Price at Filing: $18.27
Real-time Price: $12.79 info
Change: -$5.48 (-30%) info
Market Cap: $1.422B info
ADRX
Sep 25, 2026, 4:11 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $18.65
Real-time Price: $12.79 info
Change: -$5.86 (-31%) info
Market Cap: $1.422B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets